Investing Center Preview – Manage your investments and watch your net worth grow.
ABBV:NYSE – Large Cap Stock (Drug Manufacturers)
AbbVie Inc – ABBV Stock Overview
Last Price | Today's Change | 52-Week Range | Trading Volume |
---|---|---|---|
186.96 | -14.68 (-7.28%) | 153.58 - 218.66 | 13.5 million (Above Avg) |
Market data as of 4:01PM 04/04/25. Quotes are delayed by at least 15 min.
Overview - ABBV
Open | 200.00 |
---|---|
Previous Close | 201.64 |
Day's Range | 186.17 - 200.00 |
Market Cap | 330.7B |
Avg Volume (10 Day) | 8.5M |
Price/Earnings (Trailing 12 Mo.) | 78.2x |
Earnings Per Share (Trailing 12 Mo.) | 1.819 |
Dividend Yield | 1.64 (3.51%) |
One-Click Scorecard - ABBV


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Performed well consistently? | Fail |
---|---|
Avoids excess debt? | Fail |
Converting sales to profits? | Fail |
Shareholder's money handled rationally? | Pass |
Increased shareholder value? | Fail |
Consistently increased owner earnings? | Pass |
Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Pays a cash dividend? | Neutral |
---|---|
Room to increase dividends? | Fail |
Increased earnings over time? | Neutral |
Borrows within reasonable limits? | Fail |
Stock is undervalued? | Fail |
Have investors caught on? | Fail |
Has support of institutional investors? | Pass |
Has sufficient liquidity? | Pass |
Latest Headlines - ABBV
AbbVie to Host First-Quarter 2025 Earnings Conference Call
PR Newswire - Monday 03/31/2025 8:00 AM ET
AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025
PR Newswire - Wednesday 03/26/2025 8:30 AM ET
The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors
Business Wire - Wednesday 03/26/2025 8:00 AM ET
Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025
PR Newswire - Monday 03/24/2025 4:02 AM ET
ELAHERE® (mirvetuximab soravtansine-gynx) Shows Consistent Survival Benefit in Long-Term Analysis for Certain Ovarian Cancer Patients
PR Newswire - Saturday 03/15/2025 8:00 AM ET
Industry Position - ABBV
ABBV | Industry Range | |
---|---|---|
Revenue Growth (1yr) | 3.71% | |
Net Income Growth (1yr) | -12.03% | |
Total Debt/Equity | 20.19 | |
LT Debt/Equity | 18.15 | |
Earnings Yield | 1.28% | |
Price/Sales | 5.88 |
Competitors - ABBV
Company | Last | Change |
---|---|---|
51.04 | +0.37% | |
Johnson & Johnson | 153.24 | -4.12% |
261.80 | -6.00% | |
Merck & Co Inc | 81.47 | -5.70% |
92.03 | -5.42% |
Data is delayed by at least 15 min.